Astellas Pharma — Deal History & Benchmarks
Market Analysis
Astellas Pharma has been involved in 7 transactions totaling $16.9B across Cardiovascular, Ophthalmology, Oncology, Immunology & Autoimmune, Rare Disease, Neurology & CNS. As both a licensor and licensee, they have demonstrated an active acquisition strategy.
Key transactions include Iveric Bio ($5.9B, 2023), Iveric Bio ($5.9B, 2024), AviadoBio ($2.2B, 2024).
Their deal activity is concentrated in Ophthalmology (29%) with Small Molecule and Gene Therapy assets representing their most common deal types.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has Astellas Pharma done?
What is Astellas Pharma's typical deal structure?
What therapeutic areas does Astellas Pharma focus on?
How has Astellas Pharma's deal activity trended over time?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.